Evidence map›Paper›PMID 33748276›Full record

ArticleBioMed research international2021

Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2.

Taohui Zeng, Lin Luo, Yuye Huang, Xiaoli Ye, Jinhai Lin

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Epigallocatechin Gallate Derivative YRecent patents on anti-cancer drug discovery · 2025
    Article
  4. Review
  5. Article
  6. Linc-ROR Promotes EMT by Targeting miR-204-5p/SMAD4 in Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2023
    Article
  7. Review
  8. Review
  9. Review
  10. Circular RNAs in hepatocellular carcinoma: Recent advances.World journal of gastrointestinal oncology · 2022
    Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Taohui ZengDepartment of Pharmacy, First Affiliated Hospital, Gannan Medical College, Ganzhou, Jiangxi, China.
Lin LuoDepartment of Pharmacy, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi, China.
Yuye HuangDepartment of Pharmacy, The Affiliated Cangnan Hospital of Wenzhou Medical University, The People's Hospital of Cangnan, Wenzhou, Zhejiang, China.
Xiaoli YeDepartment of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
Jinhai LinDepartment of Pharmacy, First Affiliated Hospital, Gannan Medical College, Ganzhou, Jiangxi, China.ORCID https://orcid.org/0000-0003-1914-0647
First Affiliated Hospital of Gannan Medical University · CNHangzhou First People's Hospital · CNJiangxi Maternal and Child Health Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapeutic insensitivity is a major obstacle for effective treatment of hepatocellular carcinoma (HCC). Recently, new evidence showed that microRNAs (miRNAs) are closely related to drug sensitivity. This study aimed to investigate the relationship between miR-138 expression and cisplatin sensitivity of HCC cells by regulation of EZH2. CCK-8, EdU, and western blotting are determining the cell viability, proliferation, EZH2, and EMT-related protein expression. It was found that compared with normal samples, miR-138 expression was lower in cancer tissue; it was also downregulated in HCC cells. Transfected with miR-138 mimic increased sensitivity of HCC cells to cisplatin. Mechanistically, Luciferase Reporter analysis verified the interaction between miR-138 and target gene EZH2. Inhibition of EZH2 enhanced cisplatin sensitivity and transfection with EZH2 mimic mirrored the function of miR-138 in cisplatin sensitivity. Furthermore, the role of miR-138 on reversed cisplatin-induced epithelial-mesenchymal transition (EMT) was attenuated when combined with EZH2 plasmid. In conclusion, all data from this study illustrate that miR-138 may as a tumor suppressor provides a potential treatment method to treating HCC.

Indexed as

Carcinoma, HepatocellularCisplatinDrug Resistance, NeoplasmEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMicroRNAsNeoplasm ProteinsRNA, NeoplasmUp-RegulationCisplatinEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanMicroRNAsMIRN138 microRNA, humanNeoplasm ProteinsRNA, Neoplasm

Identifiers

PMID33748276
PMCPMC7960019
OpenAlexW3135446133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.